Table 2.

Outcomes after hematopoietic cell transplantation (grouped by rejection status and diagnoses)

UPNDiagnosis% donor CD3+RejectionDLIGVHDSurvival,
days
Summary of outcome as of 4/1/00
Day
28
Day
56
Acute (grade)Chronic
UL 6072-153 ALL-REL385100Yes* I3562-155 CR → REL → chemo/DLI → CR → Aspergillus
 5772-153 MF-AML-IF8485IIILim-S> 621CR
FH 142412-154 AML-aplasia85950Ext-S, G > 549CR
 134612-153 AML-CR14643Yes × 2II Ext-S> 759Rel → chemo → CR → DLI → REL → chemo
 145602-159 AML-CR14099Yes0> 473CR
UL 6462-153 AML-CR160NEYes* II Lim-S> 341Rel → DLI → CR → Rel → chemo/DLI → CR
 6272-159 AML-CR1NENE0> 410CR
 6362-159 AML-CR15863IIILim-S> 383CR
UL 6162-159 AML-CR25550Yes* 01722-155 Rel → PD
FH 133612-153 AML-CR35090Yes* IIExt-S, G1682-155 Rel × 2 → DLI → CR mucor infection
SU 18572-153 AML-IF50NE0NE382-155 PD → conventional BMT
FH 129142-153 CLL-REL2100100IIExt-S, O 3612-155 MCR Pneumococcal sepsis
SU 18792-153 CLL-PR25686IIIExt-S, G> 528MCR
FH 145872-159 CLL-REF10200Ext-S, L, O> 368PR
 145862-159 CLL-REF9080Yes* IIExt-S, L2442-155 PD
SU 20282-159 CLL-PR23025Yes* 0> 375PR → PD
FH 143222-159 CLL-REF6595IExt-E, O, S> 319MCR
 146272-159 CLL-REF7196IIIExt-L, O, S> 325CR
UL 5962-153 CML-AP7995Yes* II Lim-S> 530MCR
UL 6052-153 CML-CP27320Lim-S> 488MCR
FH 142142-159 CML-CP4550IIExt-O, S> 393MCR
UL 6342-159 CML-CP4370ILim-O> 390MCR
FH 147262-159 CML-CP2-160 10095IIExt-E, G, L, O, S> 368MCR
SU 19552-153 HD-CR26090Yes × 201642-155 PD
FH 138172-159 HD-PR9999IIExt-E, G, O, S> 464CR
 142262-159 HD-REF5992Yes* IIExt-S> 444CR → Rel → XRT/chemo + DLI → PR
 146922-159 HD-REF7090Yes* II NE1592-155 PD → Aspergillus infection
 135272-159 MM-PR9997IIExt-E, O, S> 416CR
 139222-159 MM-PR8394Yes0> 417CR2-164
 119242-159 MM-PR94970> 473CR2-164
 135412-159 MM-REF98100IINE912-155 PD
 142742-159 MM-REF9095IIExt-G, S> 310CR
UL 6252-159 MM-REF100NEIIINE542-155 PR. Pneumonia, multiorgan failure
FH 142242-159 NHL-REF88100IINE642-155 CR. Intracranial hemorrhage
 144132-159 WM-REF5862IIExt-E, O, S> 380SD
 146582-159 WM-REF8590Yes × 2* 0Lim-S, O> 333SD
UL 6442-159 AML-CR1205YesYes01332-155 Rel → 2nd NMHCT → engrafted → PD
 142842-159 CLL-PR1924YesYes0> 376PD
 140912-153 CML-AP4030YesYesI2272-155 PD → Conventional BMT
SU 20002-159 CML-AP2530YesYes04072-155 PD → 2nd NMHCT → rejected → PD
SU 19482-153 CML-CP6030YesYes0> 501PD → 2nd NMHCT → rejected
UL 6222-159 CML-CP108YesYes0> 341PD
FH 130092-153 MDS-RAEB-T4035YesYes01832-155 PD + liver cirrhosis
 132462-153 MM-REF4335YesYes0> 731PD psoriasis in CR
 132302-153 MM-PR155YesYes0> 751REL
  • GVHD indicates graft-versus-host disease; DLI, donor lymphocyte infusion; NE, not evaluable; PD, progressive disease; BMT, bone marrow transplantation; MCR, molecular remission; XRT, radiation therapy; SD, stable disease; NMHCT, nonmyeloablative hematopoietic cell transplantation; TBI, total-body irradiation; MMF, mycophenolate mofetil; and CSP, cyclosporine. For other abbreviations, see Table 1.

  • * Indicates initial DLI given for relapse or progressive disease.

  • Indicates GVHD first occurred after DLI.

  • Indicates GVHD resolved; patient off immunosuppressive therapy. GVHD extent: Lim indicates limited GVHD; Ext, extensive GVHD. GVHD organ involvement: E indicates eyes; G, gastrointestinal; L, liver; O, oral; S, skin.

  • F2-153 Cohort 1: CSP scheduled day −1 to +35.

  • F2-155 Patient died.

  • F2-154 CSP taper delayed to day +100 to prevent GVHD because of active fungal infection.

  • F2-159 Cohort 2: CSP scheduled day −1 to +56.

  • F2-160 Patient 14726 received fludarabine 30 mg/m2 × 3 in addition to TBI/MMF/CSP.

  • F2-164 Trace monoclonal protein detected intermittently by immunofixation after CR was achieved.